Quick Answer
Andrew Huberman has discussed at least 18 named peptides across two dedicated episodes of the Huberman Lab podcast, covering tissue repair, growth hormone secretion, longevity, sexual health, and sleep. None of the compounds he has discussed are FDA-approved for the uses described on the show, and most lack completed human clinical trials.
Every Peptide Discussed on Huberman Lab
Huberman Lab has dedicated two full episodes to peptide therapeutics, making it one of the most referenced mainstream sources for peptide information. The April 1, 2024 solo episode (“Benefits & Risks of Peptide Therapeutics for Physical & Mental Health,” approximately 1 hour 22 minutes) provided a structured taxonomy of therapeutic peptides divided into four categories. The October 7, 2024 guest episode with Dr. Craig Koniver (Episode 197, approximately 2 hours 29 minutes) went deeper into clinical applications, sourcing, and Huberman’s own personal results with specific compounds.
Between these two episodes, Huberman named, explained, or personally endorsed nearly twenty distinct peptides and related compounds. The table below catalogues every peptide discussed, which episode covered it, and what was claimed.
| Peptide | Episode(s) | Category Discussed | Key Claims Made |
|---|---|---|---|
| BPC-157 | Apr 2024, Oct 2024 | Tissue Repair | Promotes angiogenesis and wound healing; tumour risk caveat; most data from animal studies |
| TB-500 (Thymosin Beta-4) | Apr 2024, Oct 2024 | Tissue Repair | Promotes cell migration and extracellular matrix repair; not directly growth-promoting |
| Pentadeca Arginate (PDA) | Oct 2024 | Tissue Repair | Described as near-identical to BPC-157 with one amino acid salt substitution; physician-prescribed alternative |
| Sermorelin | Apr 2024, Oct 2024 | GH Secretagogue | GHRH analogue; discussed as part of secretagogue stacking with ipamorelin |
| Tesamorelin | Apr 2024, Oct 2024 | GH Secretagogue | GHRH analogue; discussed alongside sermorelin and CJC-1295 |
| CJC-1295 | Apr 2024, Oct 2024 | GH Secretagogue | Discussed in stacking context with ipamorelin |
| Ipamorelin | Apr 2024, Oct 2024 | GH Secretagogue | Most selective secretagogue; Koniver discussed bedtime timing and conservative dosing in clinical context |
| Hexarelin | Apr 2024, Oct 2024 | GH Secretagogue | Most potent GH stimulator; may increase prolactin; receptor desensitisation risk |
| GHRP-6 | Oct 2024 | GH Secretagogue | Discussed for appetite stimulation and sleep effects |
| MK-677 (Ibutamoren) | Apr 2024, Oct 2024 | GH Secretagogue | Oral non-peptide; appetite as a prominent side effect |
| Semaglutide | Oct 2024 | GLP-1 Agonist | Weight loss, brain health, inflammation; microdosing discussed by Koniver |
| Epitalon | Apr 2024, Oct 2024 | Longevity | DNA repair; circadian rhythm; animal vision studies; caution on lack of human data |
| Pinealon | Oct 2024 | Sleep / Longevity | Huberman’s personal result: doubled REM sleep from ~1.5 to ~3 hours over 4-6 months |
| Thymosin Alpha-1 | Oct 2024 | Immune Modulation | Koniver’s top immune peptide; autoimmune and long COVID applications |
| Cerebrolysin | Oct 2024 | Neuroprotection | Brain-derived neurotrophic factor cocktail; Koniver noted depressed mood in patients post-treatment |
| Melanotan II | Apr 2024 | Vitality | Skin pigmentation, libido; warnings about nausea, blood pressure, melanoma risk |
| PT-141 (Vyleesi) | Apr 2024 | Vitality | Libido and mood enhancement; FDA-approved as Vyleesi; side effects noted |
| Kisspeptin | Apr 2024 | Vitality | Upstream hormone regulator; GnRH stimulation; menopause symptom management |
The bottom line: Huberman Lab has covered at least 18 named peptides across two dedicated episodes, making it one of the most comprehensive mainstream podcast sources for peptide information – but the show consistently warns that most evidence comes from animal studies, not human clinical trials.
The Two Peptide Episodes: What Each One Covered
Episode 1: Solo Deep Dive (April 1, 2024)
Huberman’s solo episode organised peptides into four functional categories: tissue rejuvenation and repair (BPC-157 and TB-500), growth and metabolism (sermorelin, tesamorelin, CJC-1295, ipamorelin, hexarelin, MK-677), longevity (epitalon), and vitality (melanotan II, PT-141, and kisspeptin). The episode’s structure followed a consistent pattern for each peptide: proposed mechanism, evidence quality, potential benefits, and explicit risk warnings.
Three points from this episode stand out for their editorial significance. First, Huberman explicitly stated that BPC-157 can promote angiogenesis at tumour sites, making it unsuitable for anyone with an existing tumour or cancer concern – a warning that many online peptide promoters omit. Second, he was unusually cautious about epitalon, noting “potential anti-aging benefits” while stressing that human evidence is essentially absent. Third, his discussion of kisspeptin introduced a compound that most peptide-focused podcasts ignore entirely, framing it through reproductive endocrinology rather than performance enhancement.
The April 2024 episode ran approximately 1 hour 22 minutes, with timestamped sections beginning at 14:48 (BPC-157), 36:43 (TB-500), 45:25 (secretagogues), and 1:06:12 (longevity).
Episode 2: Dr. Craig Koniver Guest Episode (October 7, 2024)
The Koniver episode ran nearly 2.5 hours and covered significantly more ground. Koniver, a physician trained at Brown University and Thomas Jefferson University who operates a performance medicine practice, introduced several compounds that the solo episode had not covered. These included pentadeca arginate (the arginate-salt alternative to BPC-157), GHRP-6, semaglutide (in a GLP-1 microdosing context), thymosin alpha-1, cerebrolysin, and most notably, pinealon.
The Koniver episode also addressed practical aspects that the solo episode avoided: compounding pharmacy sourcing, the Category 2 FDA restriction (which Koniver described as a significant blow to legitimate clinical use), lipopolysaccharide contamination risks, and physician oversight as a non-negotiable requirement. At 34:48, the conversation turned to black and grey market sourcing, with both Huberman and Koniver warning about the dangers of unregulated supply.
For compound-specific mechanism, evidence, and regulatory information on any peptide named above, see the relevant PeptideGuider compound guide. This article indexes what was discussed on the show – the individual guides provide the science in depth.
Huberman’s Personal Peptide Disclosures
The most striking personal finding Huberman has shared about any peptide involves pinealon, a bioregulator tripeptide from the Khavinson programme. Over four to six months of tracked use, Huberman reported that pinealon doubled his REM sleep – from approximately 1 to 1.5 hours per night to nearly 3 hours – as measured by objective sleep tracking. He stated during the October 2024 episode that he had never previously found any compound or supplement capable of meaningfully increasing REM sleep duration.
Perhaps more unusually, Huberman noted that his sleep improvements persisted on nights when he did not take pinealon, suggesting a possible regenerative effect on pinealocyte function rather than simple pharmacological action. Koniver confirmed that this pattern was consistent across his patient population, though the response timeline varied. There is no published clinical trial supporting this observation. The related peptide epitalon has been shown to stimulate melatonin synthesis in pinealocyte cell cultures in studies from Khavinson’s group, but no equivalent study exists for pinealon.
Huberman also disclosed using BPC-157 prior to its Category 2 restriction and described compounding pharmacy sourcing as distinctly different from grey market products in terms of purity standards. He emphasised physician partnerships as essential for anyone considering peptide use.
The bottom line: Huberman’s personal pinealon disclosure is one of the few specific, tracked, first-person peptide outcomes reported by a neuroscientist with a relevant academic position, though it remains anecdotal and uncontrolled.
How Huberman Categorises Peptides
Huberman organises peptides into a four-tier framework that reflects functional application rather than chemical classification. This taxonomy shaped how millions of listeners first encountered peptide therapeutics and continues to influence how the broader public understands the space.
- Tier 1 – Tissue Rejuvenation and Repair: BPC-157, TB-500, and pentadeca arginate. Huberman frames these through angiogenesis, cell migration, and extracellular matrix repair.
- Tier 2 – Growth and Metabolism: The growth hormone secretagogues (sermorelin, tesamorelin, CJC-1295, ipamorelin, hexarelin, MK-677) and GLP-1 agonists (semaglutide). He discusses these through the GH/IGF-1 axis and metabolic pathways.
- Tier 3 – Longevity: Epitalon and pinealon. Huberman is notably more cautious here than in Tiers 1 and 2, repeatedly stressing the absence of human evidence for epitalon’s proposed telomerase and DNA repair mechanisms.
- Tier 4 – Vitality: Melanotan II, PT-141, and kisspeptin. These are framed through mood, libido, and hormonal signalling, with specific side-effect warnings for melanotan II.
The October 2024 episode added two categories that the solo episode did not explicitly include: immune modulation (thymosin alpha-1) and neuroprotection (cerebrolysin).
What Huberman Gets Right – and Where to Be Cautious
Huberman is more careful than most public figures discussing peptides. He consistently flags the tumour risk associated with angiogenesis-promoting compounds like BPC-157. He distinguishes between animal evidence and human clinical data. He warns about grey market contamination. And his framework for categorising peptides by function rather than hype provides a structure that many newcomers to the topic find genuinely useful.
That said, three limitations are worth noting. First, the Koniver episode featured a clinician whose practice is built around prescribing these compounds, which creates an inherent framing bias toward clinical utility. Second, Huberman’s personal pinealon endorsement – while transparently reported – carries significant influence given his audience of millions, despite being a single anecdotal account with no control, blinding, or washout period. Third, neither episode adequately addressed the single-laboratory problem with BPC-157 research: a February 2026 STAT News investigation found that 35 of the 36 studies in BPC-157’s evidence base came from a single research group in Zagreb.
Huberman’s peptide episodes are educational resources, not medical guidance. No peptide discussed on the show should be self-administered without physician oversight, and the regulatory landscape has changed significantly since these episodes aired. For current regulatory status, see the FDA Category 1 vs Category 2 explainer and the RFK Reclassification Tracker.
Regulatory Changes Since These Episodes Aired
The peptide regulatory landscape has shifted substantially since October 2024. On April 15, 2026, the FDA removed 12 peptides from the Category 2 restricted list, referring them to the Pharmacy Compounding Advisory Committee for formal review. Seven of these – including BPC-157, TB-500, KPV, and MOTS-c – are scheduled for PCAC review on July 23-24, 2026. Five more, including GHK-Cu and LL-37, are set for a February 2027 session. For a full breakdown, see the PCAC July 2026 Meeting Tracker.
Several compounds Huberman discussed have also seen regulatory movement internationally. BPC-157 remains Schedule 4 in Australia since June 2024 and is prohibited under WADA’s S0 category. TB-500 is WADA S2 prohibited and Schedule 4 in Australia. For country-specific legal information, see the US, UK, and Australian legality guides.
The bottom line: Regulatory status has changed materially since Huberman’s episodes aired, and any claims about legality or compounding access made in those episodes should be verified against current sources before acting on them.
Huberman Lab is one of the most influential mainstream sources for peptide information – but influence is not the same as clinical evidence, and no podcast episode replaces a physician relationship.
How to Use This Index
This page is designed as a reference index for anyone who heard a peptide mentioned on Huberman Lab and wants to understand what the evidence actually says. For every compound listed above, PeptideGuider maintains a dedicated guide covering mechanism of action, clinical evidence with tier labels, regulatory status by country, and safety profile. The links in the table and throughout this article point to those guides.
If you are interested in the broader topic of peptide sourcing and safety, the vendor evaluation guide and COA reading guide cover the quality and contamination issues that both Huberman and Koniver discussed at length.
This article is for informational purposes only. PeptideGuider.com does not provide medical advice, recommend any treatment, or endorse any product. Peptides discussed on Huberman Lab or any other media source should not be self-administered. Consult a qualified healthcare provider before considering any peptide therapy.